Similar Goals, Divergent Paths: Exploring Approaches to Hepatitis C Treatment Protocols in Heart Transplantation

IF 8.2 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Journal of Cardiac Failure Pub Date : 2025-12-01 Epub Date: 2025-02-01 DOI:10.1016/j.cardfail.2024.11.020
ROOPA A. RAO MBBS , SONU ABRAHAM MBBS , AMANDA R. VEST MBBS , MRUDULA MUNNAGALA MBBS , ANJU BHARDWAJ MBBS , JOHANAS CONTRERAS MD , INDRANEE RAJAPREYER MBB , SHELLEY HALL MD
{"title":"Similar Goals, Divergent Paths: Exploring Approaches to Hepatitis C Treatment Protocols in Heart Transplantation","authors":"ROOPA A. RAO MBBS ,&nbsp;SONU ABRAHAM MBBS ,&nbsp;AMANDA R. VEST MBBS ,&nbsp;MRUDULA MUNNAGALA MBBS ,&nbsp;ANJU BHARDWAJ MBBS ,&nbsp;JOHANAS CONTRERAS MD ,&nbsp;INDRANEE RAJAPREYER MBB ,&nbsp;SHELLEY HALL MD","doi":"10.1016/j.cardfail.2024.11.020","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Heart transplantation from hepatitis C-positive donors is on the rise, yet there exists divergence in approaches to managing recipients of these organs. Practices range from prophylactic treatment of recipients prior to transplantation to delayed treatment following the detection of viremia, with no established consensus on the optimal approach.</div></div><div><h3>Methods</h3><div>An online survey was conducted among the heart transplant centers in the United States and Canada from January 2023–February 2024. The survey gathered comprehensive information from the institutions regarding direct antiviral (DAA) therapies used, timing and duration of DAA, frequency of viral load testing, adverse effects, virological response, and immunosuppressive therapy modifications. The treatment pathways were categorized based on the timing of treatment initiation into prophylactic, preemptive or reactive approaches. Analysis was restricted to adult transplant programs in the U.S. that had an HCV transplant protocol and performed at least 1 HCV NAT-positive transplant. The Scientific Registry of Transplant Recipients database was queried for total heart transplants using hepatitis C virus nucleic acid testing (HCV NAT)-positive donors.</div></div><div><h3>Results</h3><div>Of 122 heart transplant programs, 35 (28.7%) institutions responded; 689 heart transplants (49.1%) using HCV NAT-positive donors were captured across institutions. Among 30 U.S. institutions performing adult heart transplantation with HCV NAT-positive donor hearts, 5 (16.7%) used prophylactic, 9 (30%) preemptive and 16 (53.3%) reactive treatment pathways. Most employed pan-genotype DAA therapies for a median of 12 weeks. Significant heterogeneity existed in treatment and monitoring protocols.</div></div><div><h3>Conclusion</h3><div>Practice patterns for management of HCV NAT-positive donor hearts vary significantly. Establishing registries and randomized control trials for these patients is crucial for guiding future practices.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 12","pages":"Pages 1795-1805"},"PeriodicalIF":8.2000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiac Failure","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1071916425000387","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/1 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Heart transplantation from hepatitis C-positive donors is on the rise, yet there exists divergence in approaches to managing recipients of these organs. Practices range from prophylactic treatment of recipients prior to transplantation to delayed treatment following the detection of viremia, with no established consensus on the optimal approach.

Methods

An online survey was conducted among the heart transplant centers in the United States and Canada from January 2023–February 2024. The survey gathered comprehensive information from the institutions regarding direct antiviral (DAA) therapies used, timing and duration of DAA, frequency of viral load testing, adverse effects, virological response, and immunosuppressive therapy modifications. The treatment pathways were categorized based on the timing of treatment initiation into prophylactic, preemptive or reactive approaches. Analysis was restricted to adult transplant programs in the U.S. that had an HCV transplant protocol and performed at least 1 HCV NAT-positive transplant. The Scientific Registry of Transplant Recipients database was queried for total heart transplants using hepatitis C virus nucleic acid testing (HCV NAT)-positive donors.

Results

Of 122 heart transplant programs, 35 (28.7%) institutions responded; 689 heart transplants (49.1%) using HCV NAT-positive donors were captured across institutions. Among 30 U.S. institutions performing adult heart transplantation with HCV NAT-positive donor hearts, 5 (16.7%) used prophylactic, 9 (30%) preemptive and 16 (53.3%) reactive treatment pathways. Most employed pan-genotype DAA therapies for a median of 12 weeks. Significant heterogeneity existed in treatment and monitoring protocols.

Conclusion

Practice patterns for management of HCV NAT-positive donor hearts vary significantly. Establishing registries and randomized control trials for these patients is crucial for guiding future practices.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
相似的目标,不同的路径:探索丙型肝炎心脏移植治疗方案的方法。
背景:丙型肝炎阳性供者的心脏移植呈上升趋势,但在管理这些器官接受者的方法上存在分歧。实践范围从移植前对受者进行预防性治疗到检测到病毒血症后的延迟治疗,对于最佳方法尚无既定共识。方法:于2023年1月至2024年2月对美国和加拿大的心脏移植中心进行在线调查。该调查从各机构收集了有关使用的直接抗病毒(DAA)治疗、DAA治疗的时间和持续时间、病毒载量检测的频率、不良反应、病毒学反应和免疫抑制治疗修改的全面信息。治疗途径根据治疗开始的时间分为预防、先发制人或反应性方法。分析仅限于具有HCV移植方案并至少进行一次HCV NAT阳性移植的美国成人移植项目。在SRTR数据库中查询使用HCV NAT阳性供者的全部心脏移植。结果:122个心脏移植项目中,有35个(28.7%)机构回应。各机构共发现689例(49.1%)使用HCV NAT阳性供者进行心脏移植。在美国30家采用HCV NAT阳性供体心脏进行成人心脏移植的机构中,5家(16.7%)采用预防性治疗途径,9家(30%)采用先发制人治疗途径,16家(53.3%)采用反应性治疗途径。大多数采用泛基因型DAA治疗,中位时间为12周。治疗方案和监测方案存在显著的异质性。结论:HCV NAT阳性供者心脏处理的实践模式差异较大。为这些患者建立登记和随机对照试验对于指导未来的实践至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Cardiac Failure
Journal of Cardiac Failure 医学-心血管系统
CiteScore
7.80
自引率
8.30%
发文量
653
审稿时长
21 days
期刊介绍: Journal of Cardiac Failure publishes original, peer-reviewed communications of scientific excellence and review articles on clinical research, basic human studies, animal studies, and bench research with potential clinical applications to heart failure - pathogenesis, etiology, epidemiology, pathophysiological mechanisms, assessment, prevention, and treatment.
期刊最新文献
Performance of the HFpEF-ABA, H2FPEF, and HFA-PEFF Algorithms in HFpEF: A Participant-Level Pooled Analysis of Randomized Clinical Trials. Importance of the Physiological Examination in Cardiogenic Shock. Table of Contents Masthead Editorial Board
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1